Rank
54
Pfizer
A blister pack containing Neurontin anti-epileptic capsules, produced by Pfizer Inc., sits on a pharmacy counter in this arranged photograph in London, U.K., on Thursday, Dec. 29, 2016. The rapid pace of innovation among drugmakers may continue to be overshadowed by broader investment themes, such as the switch away from defensive stocks into more cyclical industries, during 2017, according to Bloomberg Intelligence. Photographer: Chris Ratcliffe/Bloomberg via Getty ImagesChris Ratcliffe — Bloomberg via Getty Images
- Previous Rank55
- Revenues ($M)52824
- Revenue Percent Change8.1
- Profits ($M)7215
- Profits Percent Change3.7
- Assets ($M)171615
- Employees96500
- Market Value — as of March 31, 2017 ($M)203725
Pfizer landed one of 2016's most sought-after biopharma deals with its $14 billion acquisition of cancer drug maker Medivation, beating out the likes of Sanofi. In another critical business decision, the firm announced last fall that it wouldn't split into two publicly traded companies in order to separate its generic and branded pharmaceutical businesses, raising the prospect of even more future deals. Pfizer also came under fire over drug price increases including a record $107 million fine by U.K. regulators for hiking an epilepsy treatment's price by 2,600%.
Company Info
| CEO | Ian C. Read |
| CEO Title | Chairman & Chief Executive Officer |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| HQ Location | New York, NY |
| Website | www.pfizer.com |
| Years on Fortune 500 List | 23 |
| Employees | 96,500 |
Key Financials (Last Fiscal Year)
| Revenues ($M) | $52,824 |
| Profits ($M) | $7,215 |
| Assets ($M) | $171,615 |
| Total Stockholder Equity ($M) | $59,544 |
| Market Value — as of March 31, 2017 ($M) | $203,725 |
Profit Ratios
| Profit as % of Revenues | 13.7% |
| Profits as % of Assets | 4.2% |
| Profits as % of Stockholder Equity | 12.1% |
Earnings Per Share (Last Fiscal Year)
| Earnings Per Share ($) | 1 |
| EPS % Change (from 2015) | 5.4% |
| EPS % Change (5 year annual rate) | -1.6% |
| EPS % Change (10 year annual rate) | -7.9% |
Total Return
| Total Return to Investors (2016) | 4.4% |
| Total Return to Investors (5 year, annualized) | 12.3% |
| Total Return to Investors (10 year, annualized) | 6.8% |